Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database
Arleigh McCurdy,
Martha Louzada,
Christopher P. Venner,
Alissa Visram,
Esther Masih‐Khan,
Moustafa Kardjadj,
Victor H. Jimenez‐Zepeda,
Richard LeBlanc,
Michael Sebag,
Kevin Song,
Darrell White,
Hira Mian,
Julie Stakiw,
Anthony Reiman,
Muhammad Aslam,
Rami Kotb,
Engin Gul,
Donna Reece
Affiliations
Arleigh McCurdy
The Ottawa Hospital Ottawa Ontario Canada
Martha Louzada
London Regional Cancer Center London Ontario Canada
Christopher P. Venner
Cross Cancer Institute University of Alberta Edmonton Alberta Canada
Alissa Visram
The Ottawa Hospital Ottawa Ontario Canada
Esther Masih‐Khan
Princess Margaret Cancer Centre Toronto Ontario Canada
Moustafa Kardjadj
Canadian Myeloma Research Group Vaughan Ontario Canada
Victor H. Jimenez‐Zepeda
Arnie Charbonneau Cancer Institute University of Calgary Calgary Alberta Canada
Richard LeBlanc
Maisonneuve‐Rosemont Hospital Research Centre University of Montreal Montreal Quebec Canada
Michael Sebag
McGill University Montreal Quebec Canada
Kevin Song
BC Cancer Agency Vancouver General Hospital Vancouver British Columbia Canada
Darrell White
Queen Elizabeth II Health Sciences Centre Dalhousie University Halifax Nova Scotia Canada
Hira Mian
Juravinski Cancer Center Hamilton Ontario Canada
Julie Stakiw
Saskatoon Cancer Centre University of Saskatchewan Saskatoon Saskatchewan Canada
Anthony Reiman
Saint John Regional Hospital Saint John New Brunswick Canada
Muhammad Aslam
Allan Blair Cancer Centre Regina Saskatchewan Canada
Rami Kotb
Cancer Care Manitoba Winnipeg Manitoba Canada
Engin Gul
Canadian Myeloma Research Group Vaughan Ontario Canada
Donna Reece
Princess Margaret Cancer Centre Toronto Ontario Canada
Abstract Carfilzomib is an active and commonly used treatment in patients with multiple myeloma (MM). Using the Canadian Myeloma Research Group Database, we performed a retrospective observational study of patients treated with carfilzomib for relapse of MM in a real‐world setting in Canada between years 2007 and 2020. A total of 445 patients were included in this study: the doublet (Kd/p, n = 218) and triplets (KCd, n = 88; KRd, n = 99; KPd/p, n = 40). One hundred and twenty‐two (27%) received carfilzomib‐based treatment in line 2, 133 (30%) in line 3, 90 (20%) in line 4, and 100 (23%) in line 5 or higher. Carfilzomib was dosed weekly in 40% of patients and twice weekly in 60%. The overall response rate of the entire cohort was 57.7%, with 33.6% of patients achieving very good partial response or better. Median progression‐free survival for the overall cohort was 6.3 months with overall survival 19.7 months. This study provides a benchmark for carfilzomib‐based regimens in the real world, demonstrating that these regimens are effective in treating patients with relapsed MM.
